Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial

Charles Lung Cheng Huang, Tzung Jeng Hwang*, Yi Hsing Chen, Guan-Hua Huang, Ming H. Hsieh, Hsiu Hsi Chen, Hai Gwo Hwu

*此作品的通信作者

研究成果: Article同行評審

21 引文 斯高帕斯(Scopus)

摘要

Background/Purpose: To compare the efficacy and safety profile between intramuscular (IM) olanzapine and IM haloperidol plus IM lorazepam in acute schizophrenic patients with moderate to severe agitation. Methods: This was a prospective, randomized, open-label study. Acutely agitated patients with schizophrenia or schizoaffective disorder (. n=67) were randomized to receive 10mg IM olanzapine (. n=37) or 5mg IM haloperidol plus 2mg IM lorazepam (. n=30). Agitation was measured with Positive and Negative Syndrome Scale Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES) during the first 2 hours and at 24 hours after the first injection. Safety was assessed using the Simpson-Angus Scale and Barnes Akathisia Rating Scale and by recording adverse events at 24 hours following the first injection. The Clinical Global Impression-Severity scale was also rated. Results: The PANSS-EC scores decreased significantly at 2 hours after the first injection in both groups (olanzapine: -10.2, p<0.001; haloperidol+lorazepam: -9.9, p<0.001). Haloperidol plus lorazepam was not inferior to olanzapine in reducing agitation at 2 hours. There were no significant differences in PANSS-EC or ACES scores between the two groups within 2 hours following the first injection. The frequencies of adverse events and changes in Clinical Global Impression-Severity, Simpson-Angus Scale, and Barnes Akathisia Rating Scale scores from baseline to 24 hours showed no significant differences between the groups. Conclusion: The findings suggest that IM haloperidol (5mg) plus lorazepam (2mg) is not inferior to IM olanzapine (10mg) in the treatment of acute schizophrenic patients with moderate to severe agitation (. ClinialTrials.gov identifier number NCT00797277).

原文English
頁(從 - 到)438-445
頁數8
期刊Journal of the Formosan Medical Association
114
發行號5
DOIs
出版狀態Published - 1 5月 2015

指紋

深入研究「Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial」主題。共同形成了獨特的指紋。

引用此